Check Before You Invest : Gland Pharma Ltd

Snapshot

Q.1 Which industry/sub-sector does Gland Pharma Ltd belong to?

Gland Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Gland Pharma Ltd a good quality company?

Gland Pharma Ltd is a good quality company, based on a consistently good 10-year financial track record.

Q.3 Is Gland Pharma Ltd undervalued or overvalued?

Gland Pharma Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Gland Pharma Ltd a good buy now?

Gland Pharma Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Gland Pharma Ltd?

Gland Pharma Ltd revenue growth is -1.2% for FY-2025, which is below its 5-year CAGR of 9.35%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Gland Pharma Ltd?

Gland Pharma Ltd Return on capital employed is 15.87% for FY-2025, which is in line with its 5-year historical median of 16.67%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 11.25%, indicating value creation.

Q.3 Return on Asset of Gland Pharma Ltd?

Gland Pharma Ltd Return on Asset is 10.92%, which is in line with its 5-year historical median of 11.39%, indicating stable asset utilization efficiency.

Q.4 Return on Equity (ROE) of Gland Pharma Ltd?

Gland Pharma Ltd Return on equity is 11.62% for FY-2025, which is below its 5-year historical median of 12.31%, indicating the business is making worse use of its shareholders capital.

Q.5 Cash conversion cycle of Gland Pharma Ltd?

Gland Pharma Ltd Cash conversion cycle is 169 days, in line with its 5-year historical median of 169 days, indicating stable working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.41	0.46
ROE	11.62	12.31
ROCE	15.87	16.67
Cash Conversion Cycle	169 days	169 days

Q.6 Gross Profit margin of Gland Pharma Ltd?

Gland Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 39.7% for FY-2025, which is in line with its 5-year median of 39.3%, indicating stable margins.

Q.7 Operating Profit Margin of Gland Pharma Ltd?

Gland Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 35.05% for FY-2025, which is in line with its 5-year median of 34.33% indicating stable margins.

Q.8 Net Profit Margin of Gland Pharma Ltd?

Gland Pharma Ltd Net Profit Margin is 26.48% for FY-2025, is in line with with its 5-year median of 26.48%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin	39.7	39.3
Operating Profit Margin	35.05	34.33
Net Profit Margin	26.48	26.48

Q.9 Debt to Equity ratio of Gland Pharma Ltd?

Gland Pharma Ltd Debt-to-Equity ratio is 0.00, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Gland Pharma Ltd?

Gland Pharma Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Gland Pharma Ltd?

Promoters hold 51.83% of the Gland Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Gland Pharma Ltd vs industry peers?

Gland Pharma Ltd revenue CAGR is 9.35%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-1.2	8.3
Gross Profit Growth	4.3	14.7
Operating Profit Growth	2.4	11.4
Net Profit Growth	4.5	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.41	0.81
ROE	11.62	9.49
ROCE	15.87	11.91
Cash Conversion Cycle (days)	169.28	85

Valuation & price assessment

Q.1 Stock return of Gland Pharma Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -7.28% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-7.3%	8.9%	27.6%

Q.3 Valuation ratios of Gland Pharma Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	24.99	29.81	31.09
Price to Book	2.82	3.35	2.85
Price to Sales	6.76	7.46	2.79
EV to EBITDA	15.04	18.32	15.87

Check more companies

5. Wockhardt

8. Pfizer

10. Neuland Laboratories

Check trending companies

1. KEC International Ltd.

2. Aurobindo Pharma Ltd.

3. GE Vernova T&D India Ltd.

4. Avenue Supermarts Ltd.

5. Procter & Gamble Hygiene and Health Care Ltd.